Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Wallac OY has 2 pending office actions in Biotechnology & Pharmaceuticals. These matters are assigned to 2 distinct examiners and a pair of art units. OGUNTADE, ELIZABETH BISOLA is the busiest examiner, with 1 pending office action. The distribution of the pending office actions across separate art units indicates that the matters are technically distinct.
The presence of separate examiners ensures that the company receives independent reviews for each application. The busiest examiner is responsible for 1 pending office action, which matches the workload of the other official involved. Because the cases are located in separate art units, the company must address different technical requirements for each. This separation suggests that the Biotechnology & Pharmaceuticals applications cover different aspects of the company's technology.
Practitioners should prepare for different examiner perspectives while navigating the specific rules of the 2 distinct art units involved. With a total count of pending office actions that matches the number of examiners, the portfolio is small but technically diverse. The parity between actions and examiners means that no single individual has a dominant influence over the current portfolio. This structure requires a tailored approach for each official to ensure successful prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | SITTON, JEHANNE SOUAYA | 4d overdue |
| 18647364 | NEWBORN SCREENING FOR CONGENITAL HEART DEFECT USING CARDIOVASCULAR BIOMARKERS IN DRIED BLOOD SAMPLES | OGUNTADE, ELIZABETH BISOLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | SITTON, JEHANNE SOUAYA | 4d overdue |
| 18647364 | NEWBORN SCREENING FOR CONGENITAL HEART DEFECT USING CARDIOVASCULAR BIOMARKERS IN DRIED BLOOD SAMPLES | OGUNTADE, ELIZABETH BISOLA | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647364 | NEWBORN SCREENING FOR CONGENITAL HEART DEFECT USING CARDIOVASCULAR BIOMARKERS IN DRIED BLOOD SAMPLES | OGUNTADE, ELIZABETH BISOLA | 1677 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | SITTON, JEHANNE SOUAYA | 1682 | §103§112 | Non-Final OA | 4d overdue | Pending | Apr 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWallac OY has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Elizabeth Bisola Oguntade has the most, with 1 of Wallac OY's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
